Literature DB >> 29655456

Lambert-Eaton Myasthenic Syndrome.

Vita G Kesner1, Shin J Oh2, Mazen M Dimachkie3, Richard J Barohn3.   

Abstract

Lambert-Eaton myasthenic syndrome is a paraneoplastic or primary autoimmune neuromuscular junction disorder characterized by proximal weakness, autonomic dysfunction and ariflexia. The characteristic symptoms are thought to be caused by antibodies generated against the P/Q-type voltage-gated calcium channels present on presynaptic nerve terminals and by diminished release of acetylcholine. More than half of Lambert-Eaton myasthenic syndrome cases are associated with small cell lung carcinoma. Diagnosis is confirmed by serologic testing and electrophysiologic studies. 3,4-diaminopyridine is effective symptomatic treatment of LEMS.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3,4-Diaminopyridine; Lambert-Eaton myasthenic syndrome; Neuromuscular transmission disorder; P/Q-type voltage-gated calcium channels; Paraneoplastic syndrome

Mesh:

Year:  2018        PMID: 29655456      PMCID: PMC6690495          DOI: 10.1016/j.ncl.2018.01.008

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  15 in total

Review 1.  Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances.

Authors:  Elisabeth P Golden; Steven Vernino
Journal:  Clin Auton Res       Date:  2019-05-15       Impact factor: 4.435

2.  Ion Transporting Proteins and Cancer: Progress and Perspectives.

Authors:  Mustafa B A Djamgoz
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

3.  Lambert-Eaton Myasthenic Syndrome in Lung Cancer.

Authors:  Yongbin Wang; Chuanguo Xu; Yu Wang; Feifei Feng; Hui Wang; Ying Zhang; Xiaojuan Lin; Bin Xu
Journal:  Contrast Media Mol Imaging       Date:  2022-07-05       Impact factor: 3.009

4.  Five-Month Trial of Whole-Food Plant-Based Diet in a Patient With Coexisting Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.

Authors:  Peter Kim; Matthew Arnold; Jasmine Gunti
Journal:  Am J Lifestyle Med       Date:  2021-02-16

5.  Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.

Authors:  Elyse E Lower; Madison Sturdivant; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 6.  Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes.

Authors:  Konstantin A Petrov; Evgeny E Nikolsky; Patrick Masson
Journal:  Front Pharmacol       Date:  2018-07-12       Impact factor: 5.810

7.  Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome.

Authors:  Vincenzo Todisco; Giovanni Cirillo; Rocco Capuano; Alessandro d'Ambrosio; Gioacchino Tedeschi; Antonio Gallo
Journal:  Clin Neurophysiol Pract       Date:  2018-08-13

Review 8.  Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome.

Authors:  Arsalan Anwar; Sidra Saleem; Mirza Fawad Ahmed; Sara Ashraf; Sameen Ashraf
Journal:  Cureus       Date:  2019-08-21

9.  Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome with SOX-1 Antibodies.

Authors:  Shinichi Wada; Mayu Kamei; Naoko Uehara; Koji Tsuzaki; Toshiaki Hamano
Journal:  Intern Med       Date:  2020-12-15       Impact factor: 1.271

10.  Autonomic dysfunction detected by skin sympathetic response in Lambert-Eaton myasthenic syndrome: a case report.

Authors:  Jinghong Zhang; Xusheng Huang; Qiang Shi
Journal:  BMC Neurol       Date:  2022-03-19       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.